重点通报！格力电器业绩说明会：回应热点问题，聚焦未来发展

格力电器业绩说明会：回应热点问题，聚焦未来发展

2024年6月14日，格力电器召开2023年度网上业绩说明会，公司副总裁兼董秘望靖东、总工程师王军胜、财务总监董容、营销总监孟繁彬等高管出席会议，就投资者关注的热点问题进行了解答。

董明珠缺席引猜想

格力电器董事长兼总裁董明珠女士并未出席本次业绩说明会，引发了外界猜测。对此，望靖东表示，董明珠女士近期工作繁忙，无法出席会议，但对本次业绩说明会十分重视，并对公司未来的发展充满信心。

回应三大热点问题

在本次业绩说明会上，格力电器重点回应了以下三大热点问题：

• 关于公司业绩：2023年，格力电器实现营业收入2600亿元，同比增长10%；实现归属于上市公司股东的净利润247亿元，同比增长8%。公司整体业绩稳健增长，展现出强大的抗风险能力。
• 关于分红计划：格力电器一直坚持高分红政策，2023年拟派发现金红利110亿元，占可分配利润的44.5%。公司未来将继续坚持稳健分红策略，回馈投资者。
• 关于渠道改革：格力电器近年来积极推进渠道改革，加强线上线下渠道融合。公司表示，将继续深化渠道改革，打造全渠道营销体系，进一步提升市场竞争力。

聚焦未来发展

在业绩说明会的最后，格力电器高管们对公司未来的发展进行了展望。他们表示，格力电器将坚持创新驱动，持续加大研发投入，不断推出高科技、高品质的产品，满足消费者不断升级的需求。同时，公司将加快智能制造、新能源、大健康等产业转型升级，打造新的增长引擎，推动公司高质量发展。

分析与展望

格力电器2023年业绩稳健增长，展现出强大的抗风险能力。公司在渠道改革、分红政策等方面也取得了积极进展。展望未来，格力电器将继续坚持创新驱动，聚焦主业，深化转型升级，努力实现高质量发展。

值得注意的是，董明珠女士的缺席引发了外界一些猜测。 有分析人士认为，这可能与董明珠女士近期对一些行业现象的直言不讳有关。也有分析人士认为，这可能是格力电器内部权力更迭的信号。

无论如何，格力电器作为中国家电行业的龙头企业，其一举一动都备受关注。 未来，格力电器将如何发展，值得我们拭目以待。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.